Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Imfinzi shows sustained OS benefit in first-line ES-SCLC in CASPIAN trial

pharmaceutical-business-reviewJune 03, 2020

Tag: Imfinzi , CASPIAN , ES-SCLC , OS

PharmaSources Customer Service